SB17

ustekinumab biosimilar · Samsung Bioepis Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SB17, covering 2025-05-25 to 2025-05-25. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis [Phase 3]

See pricing